KPV: Research Overview

KPV is a tripeptide — just three amino acids, lysine-proline-valine — corresponding to the C-terminal end of alpha-melanocyte-stimulating hormone (α-MSH). Despite its minimal size, it has attracted sustained research interest because it retains a striking portion of the parent hormone's anti-inflammatory activity while lacking its best-known side effect: pigmentation. That combination has made KPV a distinctive tool in inflammatory-pathway research, particularly in intestinal and skin models. This overview covers its origin, mechanism, the key literature, and how researchers use it.

Origin: the α-MSH fragment program

α-MSH is a 13-amino-acid melanocortin hormone derived from proopiomelanocortin (POMC), studied for pigmentation, appetite, and — increasingly from the 1990s onward — anti-inflammatory signaling. Fragment research asked a simple question: which part of the sequence carries which activity? The answer, established across a body of published work, was that the C-terminal tripeptide KPV retained much of the anti-inflammatory activity. Crucially, the pigmentation and appetite effects map elsewhere in the molecule — so KPV allows researchers to isolate the inflammatory-pathway dimension of α-MSH biology.

How KPV works in research models

The most consequential mechanistic finding is that KPV's anti-inflammatory activity in models operates largely independently of the classic melanocortin receptors (MC1R and relatives) that mediate α-MSH's other effects. Research instead describes intracellular pathway engagement:

• NF-κB pathway: in-vitro studies report KPV reducing NF-κB activation — the master inflammatory transcription factor — in stimulated cell models, with downstream reductions in pro-inflammatory cytokine markers (including TNF-α and IL-6 families).
• PepT1 transport: a notable study (Dalmasso and colleagues, American Journal of Physiology, 2008) described KPV uptake into intestinal epithelial cells via the PepT1 peptide transporter — unusual for a signaling peptide and relevant to delivery research in gut models.
• Mucosal-immunity models: animal research in chemically induced colitis models (including work published in the Annals of the New York Academy of Sciences, 2008) reported reduced inflammatory and histological markers under research protocols.

Research timeline

Melanocortin biology expanded rapidly in the 1990s; fragment-based anti-inflammatory research followed through the 2000s, culminating in the intestinal-model and transporter studies of 2008 that defined KPV's research identity. Work since has extended into skin-inflammation models, wound-environment research, and continued mechanistic mapping of its melanocortin-receptor-independent signaling. The evidence base is preclinical.

Key published findings

• Intestinal inflammation models: animal colitis studies reported reduced inflammatory markers and improved histological endpoints under KPV research protocols.
• Transporter pharmacology: the PepT1-uptake characterization gave KPV a rare property among research peptides — a defined epithelial uptake route — making it a reference compound in peptide-delivery research.
• Skin models: cell and animal research has examined KPV in inflammatory skin models, reporting effects on cytokine-marker expression.
• Receptor-independence work: multiple studies confirmed the anti-inflammatory activity persists in models lacking functional melanocortin receptors, sharpening the search for its intracellular targets.

Context among related compounds

KPV sits at the intersection of melanocortin and repair research. It complements tissue-repair compounds such as BPC-157 — one addressing inflammatory signaling, the other growth-factor and angiogenesis pathways — and both appear in the KLOW research blend. Researchers comparing melanocortin fragments should note that KPV is specifically the non-pigmenting member of that family.

What researchers examine

Active questions include the identity of KPV's intracellular binding targets, NF-κB modulation kinetics, PepT1-mediated delivery optimization, mucosal-barrier models, and combination designs with repair-pathway peptides. Its small size also makes it a model compound for structure-activity research on minimal anti-inflammatory sequences.

Frequently asked research questions

What does KPV stand for?

Its amino-acid sequence in single-letter code: lysine (K), proline (P), valine (V) — the three C-terminal residues of α-MSH.

Does KPV cause pigmentation like α-MSH?

No — this is its defining research property. The pigmentation activity of α-MSH maps to other regions of the hormone; published work describes KPV as lacking melanogenic activity while retaining anti-inflammatory pathway effects in models.

How does KPV work if not through melanocortin receptors?

Research describes melanocortin-receptor-independent mechanisms: intracellular NF-κB pathway modulation and, in intestinal models, uptake via the PepT1 transporter. The full target map remains an open research question.

Is KPV an approved treatment?

No. It is a research compound supplied strictly for qualified in-vitro laboratory use and is not for human or veterinary use.

How is it supplied and verified?

Lyophilized powder in sealed vials, identity and purity verified at ≥99% by independent third-party HPLC analysis.

Can KPV be studied in oral-delivery models?

Yes — that is one of its distinctive research angles. The 2008 characterization of PepT1-mediated uptake in intestinal epithelium gave KPV a defined absorption route unusual among peptides, making it a reference compound in peptide oral-delivery research.

How should the research material be stored?

Lyophilized vials: frozen at -20°C or below for long-term storage, protected from light and moisture. After reconstitution under sterile laboratory conditions, keep refrigerated at 2–8°C and use within the protocol's validated window.

How the evidence base reads

KPV's literature is preclinical: cell-culture NF-κB studies, transporter pharmacology, and rodent colitis and dermatological models. It benefits from being embedded in the much larger α-MSH/melanocortin literature, which provides receptor-level context, but KPV-specific findings remain animal and in-vitro. No human trials have been completed.

Laboratory handling and stability

For long-term research storage, keep lyophilized vials frozen at -20°C or below, protected from light and moisture; short-term handling at 2–8°C is standard. Reconstitution should be performed only under sterile laboratory conditions with the laboratory-grade solvent specified by the research protocol, and reconstituted material should be kept cold, protected from light, and used within the validated window of the protocol. Record vial lot numbers and retain the certificate of analysis with study records — traceability is a baseline requirement for reproducible work.

Related research in this library

BPC-157 · GHK-Cu · KLOW Blend

Why a three-amino-acid peptide matters

KPV is a case study in minimal active sequences. Most signaling peptides are dozens of residues long, which complicates synthesis, stability, and delivery in research settings. That a tripeptide retains measurable pathway activity made KPV a reference point for two research questions at once: which residues carry α-MSH's anti-inflammatory function, and how small a peptide can be while still engaging intracellular signaling. Its PepT1 uptake route added a third distinction — most peptides of any size lack a defined epithelial transport mechanism.

Is KPV studied in skin models as well as gut models?

Yes. The two largest model families are intestinal inflammation (colitis models, epithelial transport) and skin (inflammatory and wound-environment cell models). Both leverage the same NF-κB-pathway findings.

Form, handling, and verification

KPV is supplied as a lyophilized (freeze-dried) powder in sealed vials, with identity and purity verified at ≥99% by independent third-party HPLC analysis. Lyophilized material should be stored in a cool, dry environment away from light and handled per standard laboratory protocol with appropriate protective equipment.

View KPV research material →

Research Use Only. All materials referenced are supplied strictly for qualified in-vitro laboratory research. Not for human or veterinary use, and not intended to diagnose, treat, cure, or prevent any disease. Nothing in this article constitutes medical advice, dosing guidance, or a recommendation for human use.